speb/financial-data huggingface dataset:
Financial ratios for CME — annual report dated 2023-12-31
Total revenue: 5578900000
Gross profit: 4750300000
Operating income: 3435700000
Net income: 3226200000
Capital expenditures: 76400000
Operating cash flow: 3453800000
Depreciation & amortization: 352600000
Net tangible assets: -3982900000
Owner earnings: 3502400000
Return on net tangible assets (%): -87.93592608400914
Capex to operating income (%): 2.223709869895509
Buffett classification: The Great
Stock price: 191.85
P/E ratio: 21.486320672633436
Shares outstanding: 361319613
Book value: 26737900000
P/B ratio: 2.592543459061856
Market cap (USD): 69319167754.05
Debt to equity: 0.12811028540012492
Current ratio: 1.0157712362538256
Quick ratio: 1.0157712362538256
Effective tax rate (%): 22.32761941448382
Interest coverage ratio: 21.553952321204516
COGS to revenue (%): 14.852390256143686
SG&A to revenue (%): 2.58832386312714
Free cash flow (dilution-adjusted): 3294500000
Buyback yield (%): 0
Retained earnings: 4455200000
Receivables turnover: 10.416168782673637
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.467555085259526
FCF margin (%): 59.05285988277259
Revenue growth (%): 11.146750607642348
Rule of 40 score: 70.19961049041494
Financial ratios for CME — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 204.29
Shares outstanding: 361319613
Market cap (USD): 73813983739.77
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CME — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 221.42
Shares outstanding: 361319613
Market cap (USD): 80003388710.45999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CME — annual report dated 2024-12-31
Total revenue: 6130100000
Gross profit: 5279800000
Operating income: 3931500000
Net income: 3525800000
Capital expenditures: 94000000
Operating cash flow: 3690500000
Depreciation & amortization: 336800000
Net tangible assets: -3996900000
Owner earnings: 3768600000
Return on net tangible assets (%): -94.288073256774
Capex to operating income (%): 2.3909449319598117
Buffett classification: The Great
Stock price: 221.42
P/E ratio: 22.69084710149753
Shares outstanding: 361319613
Book value: 26486900000
P/B ratio: 3.020488947761346
Market cap (USD): 80003388710.45999
Debt to equity: 0.1294224692206336
Current ratio: 1.007033257455732
Quick ratio: 1.007033257455732
Effective tax rate (%): 22.363147927951733
Interest coverage ratio: 24.434431323803604
COGS to revenue (%): 13.870899332800443
SG&A to revenue (%): 2.164728144728471
Free cash flow (dilution-adjusted): 3507000000
Buyback yield (%): 0
Retained earnings: 4185800000
Receivables turnover: 10.696388064910138
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.19030202287871
FCF margin (%): 57.20950718585341
Revenue growth (%): 9.880083887504705
Rule of 40 score: 67.08959107335812
Financial ratios for CME — quarterly report dated 2025-03-31
Total revenue: 1642300000
Gross profit: 1435600000
Operating income: 1108000000
Net income: 956200000
Capital expenditures: 14200000
Operating cash flow: 1116600000
Depreciation & amortization: 82500000
Net tangible assets: -3417300000
Owner earnings: 1024500000
Return on net tangible assets (%): -29.979808620841013
Capex to operating income (%): 1.2815884476534296
Buffett classification: The Great
Stock price: 254.19
P/E ratio: 24.012715025222235
Shares outstanding: 361319613
Book value: 27030700000
P/B ratio: 3.3977600442633746
Market cap (USD): 91843832428.47
Debt to equity: 0.1265006085672957
Current ratio: 1.0166792675353853
Quick ratio: 1.0166792675353853
Effective tax rate (%): 23.184447300771208
Interest coverage ratio: 26.570743405275778
COGS to revenue (%): 12.586007428606221
SG&A to revenue (%): 1.7353711258600741
Free cash flow (dilution-adjusted): 1081200000
Buyback yield (%): 0
Retained earnings: 4685900000
Receivables turnover: 2.132303297844716
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0430030155390897
FCF margin (%): 65.83450039578639
Rule of 40 score: 65.83450039578639
Financial ratios for CME — quarterly report dated 2025-06-30
Total revenue: 1692000000
Gross profit: 1470400000
Operating income: 1129300000
Net income: 1025100000
Capital expenditures: 18400000
Operating cash flow: 1058500000
Depreciation & amortization: 83400000
Net tangible assets: -2688700000
Owner earnings: 1090100000
Return on net tangible assets (%): -40.54375720608473
Capex to operating income (%): 1.6293279022403258
Buffett classification: The Great
Stock price: 265.3
P/E ratio: 48.38141287482966
Shares outstanding: 361319613
Book value: 27739000000
P/B ratio: 3.4557155387324707
Market cap (USD): 95858093328.90001
Debt to equity: 0.12330653592415011
Current ratio: 1.018595214951805
Quick ratio: 1.018595214951805
Effective tax rate (%): 22.94219349019018
Interest coverage ratio: 25.66590909090909
COGS to revenue (%): 13.09692671394799
SG&A to revenue (%): 2.210401891252955
Free cash flow (dilution-adjusted): 1019400000
Buyback yield (%): 0.008554311602949234
Retained earnings: 5254900000
Receivables turnover: 2.5344517675254643
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0429346683839813
FCF margin (%): 60.24822695035461
Revenue growth (%): 3.0262436826401995
Rule of 40 score: 63.27447063299481
Financial ratios for CME — quarterly report dated 2025-09-30
Total revenue: 1537600000
Gross profit: 1300000000
Operating income: 972600000
Net income: 908000000
Capital expenditures: 18400000
Operating cash flow: 968100000
Depreciation & amortization: 82600000
Net tangible assets: -2167300000
Owner earnings: 972200000
Return on net tangible assets (%): -44.85765699257141
Capex to operating income (%): 1.8918363150318733
Buffett classification: The Great
Stock price: 261.32
P/E ratio: 32.67920993637213
Shares outstanding: 361319613
Book value: 28190300000
P/B ratio: 3.349380505676066
Market cap (USD): 94420041269.16
Debt to equity: 0.12136444096018843
Current ratio: 1.021483121550507
Quick ratio: 1.021483121550507
Effective tax rate (%): 22.854715378079867
Interest coverage ratio: 22.104545454545455
COGS to revenue (%): 15.452653485952133
SG&A to revenue (%): 2.3868366285119667
Free cash flow (dilution-adjusted): 925700000
Buyback yield (%): 0
Retained earnings: 5706400000
Receivables turnover: 2.39166277803702
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.5896361302965594
FCF margin (%): 60.20421436004162
Revenue growth (%): -9.125295508274233
Rule of 40 score: 51.078918851767384
Financial ratios for CME — quarterly report dated 2025-12-31
Total revenue: 1648700000
Gross profit: 1407600000
Operating income: 1019600000
Net income: 1182900000
Capital expenditures: 32500000
Operating cash flow: 1133900000
Depreciation & amortization: 82400000
Net tangible assets: -1572500000
Owner earnings: 1232800000
Return on net tangible assets (%): -78.39745627980922
Capex to operating income (%): 3.18752451941938
Buffett classification: The Great
Stock price: 265.33
P/E ratio: 23.542294808037425
Shares outstanding: 361319613
Book value: 28728200000
P/B ratio: 3.3371019735761376
Market cap (USD): 95868932917.29
Debt to equity: 0.11912685096873456
Current ratio: 1.031582683860616
Quick ratio: 1.031582683860616
Effective tax rate (%): 25.057019766852505
Interest coverage ratio: 23.331807780320368
COGS to revenue (%): 14.623642870140111
SG&A to revenue (%): 2.9053193425122825
Free cash flow (dilution-adjusted): 1072500000
Buyback yield (%): 0.26901311212309076
Retained earnings: 6433200000
Receivables turnover: 2.579317897371715
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.6741852993246344
FCF margin (%): 65.05125250197125
Revenue growth (%): 7.225546305931322
Rule of 40 score: 72.27679880790257
Financial ratios for CME — annual report dated 2025-12-31
Total revenue: 6520600000
Gross profit: 5613600000
Operating income: 4229500000
Net income: 4072200000
Capital expenditures: 83500000
Operating cash flow: 4277100000
Depreciation & amortization: 330900000
Net tangible assets: -1572500000
Owner earnings: 4319600000
Return on net tangible assets (%): -274.69634340222575
Capex to operating income (%): 1.9742286322260314
Buffett classification: The Great
Stock price: 265.33
P/E ratio: 23.542294808037425
Shares outstanding: 361319613
Book value: 28728200000
P/B ratio: 3.3371019735761376
Market cap (USD): 95868932917.29
Debt to equity: 0.11912685096873456
Current ratio: 1.031582683860616
Quick ratio: 1.031582683860616
Effective tax rate (%): 23.605665509802083
Interest coverage ratio: 24.391580161476355
COGS to revenue (%): 13.909762905254116
SG&A to revenue (%): 2.3080698095267307
Free cash flow (dilution-adjusted): 4098800000
Buyback yield (%): 0.27756645651785367
Retained earnings: 6433200000
Receivables turnover: 10.201188986232792
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.093043079142351
FCF margin (%): 62.85924608164892
Revenue growth (%): 6.370206032528017
Rule of 40 score: 69.22945211417694
Financial ratios for CRCT — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 14.86
Shares outstanding: 55019004
Market cap (USD): 817582399.4399999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CRCT — annual report dated 2022-12-31
Total revenue: 886296000
Gross profit: 349893000
Operating income: 79953000
Net income: 60666000
Capital expenditures: 33771000
Operating cash flow: 117683000
Depreciation & amortization: 26957000
Net tangible assets: 671975000
Owner earnings: 53852000
Return on net tangible assets (%): 8.013988615647904
Capex to operating income (%): 42.238565157029754
Buffett classification: The Good
Stock price: 6.23
P/E ratio: 5.650090576599743
Shares outstanding: 55019004
Book value: 672735000
P/B ratio: 0.5095147345091307
Market cap (USD): 342768394.92
Debt to equity: 0.02879439898325492
Current ratio: 3.1932408602827724
Quick ratio: 1.8089712504329754
Effective tax rate (%): 25.99992681231017
Interest coverage ratio: 276.65397923875435
COGS to revenue (%): 60.52187982344499
R&D to revenue (%): 8.6781391318476
SG&A to revenue (%): 21.778954209428907
Free cash flow (dilution-adjusted): 42791000
Buyback yield (%): 5.420569771123867
Retained earnings: 0
Inventory turnover: 1.5252500838825984
Receivables turnover: 6.491156372904445
Capitalized R&D asset: 76914000
ROCI (R&D-adjusted, %): 16.987902677721898
FCF margin (%): 4.828070983057579
Rule of 40 score: 4.828070983057579
Financial ratios for CRCT — annual report dated 2023-12-31
Total revenue: 765147000
Gross profit: 343293000
Operating income: 69985000
Net income: 53636000
Capital expenditures: 23717000
Operating cash flow: 288097000
Depreciation & amortization: 30039000
Net tangible assets: 534873000
Owner earnings: 59958000
Return on net tangible assets (%): 11.20976381309208
Capex to operating income (%): 33.88869043366436
Buffett classification: The Good
Stock price: 4.98
P/E ratio: 5.108409275859498
Shares outstanding: 55019004
Book value: 534873000
P/B ratio: 0.5122611160406302
Market cap (USD): 273994639.92
Debt to equity: 0.026488530922293703
Current ratio: 3.1556366560794853
Quick ratio: 1.9112916361267205
Effective tax rate (%): 32.77264580173721
Interest coverage ratio: 216.67182662538698
COGS to revenue (%): 55.13371940293826
R&D to revenue (%): 8.501372938794766
SG&A to revenue (%): 27.21829922877565
Free cash flow (dilution-adjusted): 217054000
Buyback yield (%): 7.420583120142958
Retained earnings: 28514000
Inventory turnover: 1.7255930199739027
Receivables turnover: 6.877911314462413
Capitalized R&D asset: 116580380
ROCI (R&D-adjusted, %): 13.0867368910347
Rosenberg metric: -0.0858101255948202
FCF margin (%): 28.367620862396375
Revenue growth (%): -13.669135367868071
Rule of 40 score: 14.698485494528304
Financial ratios for CRCT — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 5.76
Shares outstanding: 55019004
Market cap (USD): 316909463.03999996
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CRCT — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.73
Shares outstanding: 55019004
Market cap (USD): 260239888.92000002
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CRCT — annual report dated 2024-12-31
Total revenue: 712538000
Gross profit: 352788000
Operating income: 76110000
Net income: 62830000
Capital expenditures: 18334000
Operating cash flow: 264968000
Depreciation & amortization: 29006000
Net tangible assets: 466761000
Owner earnings: 73502000
Return on net tangible assets (%): 15.74724537825568
Capex to operating income (%): 24.088818814873207
Buffett classification: The Great
Stock price: 4.73
P/E ratio: 4.141968628362248
Shares outstanding: 55019004
Book value: 466761000
P/B ratio: 0.5575442012507472
Market cap (USD): 260239888.92000002
Debt to equity: 0.032584127637056225
Current ratio: 2.8529408872323896
Quick ratio: 2.28622636128512
Effective tax rate (%): 29.30679478380233
Interest coverage ratio: 233.46625766871165
COGS to revenue (%): 50.4885353482902
R&D to revenue (%): 8.476600546216483
SG&A to revenue (%): 30.353328524233092
Free cash flow (dilution-adjusted): 201567000
Buyback yield (%): 14.791352762924474
Retained earnings: 0
Inventory turnover: 3.1213396381935707
Receivables turnover: 6.987036673857619
Capitalized R&D asset: 129362780
ROCI (R&D-adjusted, %): 11.155521898259439
Rosenberg metric: 0.14596913048825483
FCF margin (%): 28.2885965380092
Revenue growth (%): -6.875672256442226
Rule of 40 score: 21.412924281566976
Financial ratios for CRCT — quarterly report dated 2025-03-31
Total revenue: 162634000
Gross profit: 98348000
Operating income: 29341000
Net income: 23914000
Capital expenditures: 4892000
Operating cash flow: 61166000
Depreciation & amortization: 6105000
Net tangible assets: 490174000
Owner earnings: 25127000
Return on net tangible assets (%): 5.126138881295214
Capex to operating income (%): 16.67291503357077
Buffett classification: The Great
Stock price: 4.35
P/E ratio: 2.502014169524128
Shares outstanding: 55019004
Book value: 490174000
P/B ratio: 0.4882606327548992
Market cap (USD): 239332667.39999998
Debt to equity: 0.029595612986408906
Current ratio: 3.282742081712631
Quick ratio: 2.613616822156582
Effective tax rate (%): 26.691395113577144
Interest coverage ratio: 371.40506329113924
COGS to revenue (%): 39.52801997122373
R&D to revenue (%): 9.627138236777059
SG&A to revenue (%): 32.80371877959099
Free cash flow (dilution-adjusted): 45824000
Buyback yield (%): 5.0139415276495605
Retained earnings: 25997000
Inventory turnover: 0.5619552960304903
Receivables turnover: 2.248655375043208
Capitalized R&D asset: 15657000
ROCI (R&D-adjusted, %): 7.5575761951264
FCF margin (%): 28.176150128509413
Rule of 40 score: 28.176150128509413
Financial ratios for CRCT — quarterly report dated 2025-06-30
Total revenue: 172112000
Gross profit: 101539000
Operating income: 30105000
Net income: 24488000
Capital expenditures: 5702000
Operating cash flow: 36157000
Depreciation & amortization: 5978000
Net tangible assets: 308937000
Owner earnings: 24764000
Return on net tangible assets (%): 8.015873786564898
Capex to operating income (%): 18.940375352931408
Buffett classification: The Great
Stock price: 5.72
P/E ratio: 6.501977250526838
Shares outstanding: 55019004
Book value: 308937000
P/B ratio: 1.0186824591421553
Market cap (USD): 314708702.88
Debt to equity: 0.0433518808041769
Current ratio: 1.5242429484309497
Quick ratio: 1.2067798852212137
Effective tax rate (%): 27.642348491563983
Interest coverage ratio: 371.6666666666667
COGS to revenue (%): 41.004113600446225
R&D to revenue (%): 9.73900715812959
SG&A to revenue (%): 31.76536208980199
Free cash flow (dilution-adjusted): 20767000
Buyback yield (%): 1.5064724796656694
Retained earnings: 0
Inventory turnover: 0.565506907272669
Receivables turnover: 2.0991828271740456
Capitalized R&D asset: 27252190
ROCI (R&D-adjusted, %): 10.139107235403271
Rosenberg metric: 0.2038066040748547
FCF margin (%): 12.065980291902948
Revenue growth (%): 5.827809683092097
Rule of 40 score: 17.893789974995045
Financial ratios for CRCT — quarterly report dated 2025-09-30
Total revenue: 170437000
Gross profit: 94096000
Operating income: 22651000
Net income: 20512000
Capital expenditures: 6589000
Operating cash flow: 20475000
Depreciation & amortization: 6053000
Net tangible assets: 358392000
Owner earnings: 19976000
Return on net tangible assets (%): 5.573785129132347
Capex to operating income (%): 29.08922343384398
Buffett classification: The Good
Stock price: 6.02
P/E ratio: 4.80619908988014
Shares outstanding: 55019004
Book value: 358392000
P/B ratio: 0.9241679615616419
Market cap (USD): 331214404.08
Debt to equity: 0.03491707404183129
Current ratio: 2.3583336006586895
Quick ratio: 1.6370951357478158
Effective tax rate (%): 19.971909016425425
Interest coverage ratio: 123.77595628415301
COGS to revenue (%): 44.79133052095496
R&D to revenue (%): 9.895151874299595
SG&A to revenue (%): 32.02356295874722
Free cash flow (dilution-adjusted): 6502000
Buyback yield (%): 0.7104159635012937
Retained earnings: 20512000
Inventory turnover: 0.5659122751095264
Receivables turnover: 1.9249717641743844
Capitalized R&D asset: 33262350
ROCI (R&D-adjusted, %): 5.624657183503101
Rosenberg metric: -0.44404009068130296
FCF margin (%): 3.8148993469727817
Revenue growth (%): -0.9732034953983452
Rule of 40 score: 2.8416958515744364
Financial ratios for CRCT — quarterly report dated 2025-12-31
Total revenue: 203597000
Gross profit: 96448000
Operating income: 13936000
Net income: 7791000
Capital expenditures: 7234000
Operating cash flow: 82432000
Depreciation & amortization: 6303000
Net tangible assets: 343561000
Owner earnings: 6860000
Return on net tangible assets (%): 1.9967342044062044
Capex to operating income (%): 51.90872560275545
Buffett classification: The Good
Stock price: 4.74
P/E ratio: 3.3999097706798773
Shares outstanding: 55019004
Book value: 343561000
P/B ratio: 0.759079403541147
Market cap (USD): 260790078.96
Debt to equity: 0.03383387520702292
Current ratio: 2.259825850955558
Quick ratio: 1.795440461381884
Effective tax rate (%): 50.68363083934675
Interest coverage ratio: 62.214285714285715
COGS to revenue (%): 52.627985677588576
R&D to revenue (%): 8.46672593407565
SG&A to revenue (%): 32.0603938171977
Free cash flow (dilution-adjusted): 67929000
Buyback yield (%): 2.1680272587620983
Retained earnings: 3960000
Inventory turnover: 1.0436861996415492
Receivables turnover: 2.212746302072578
Capitalized R&D asset: 34069010
ROCI (R&D-adjusted, %): 3.610716007853834
Rosenberg metric: 0.13946042099021644
FCF margin (%): 33.36444053694308
Revenue growth (%): 19.4558693241491
Rule of 40 score: 52.82030986109218
Financial ratios for CRCT — annual report dated 2025-12-31
Total revenue: 708780000
Gross profit: 390431000
Operating income: 96033000
Net income: 76705000
Capital expenditures: 24417000
Operating cash flow: 200230000
Depreciation & amortization: 24439000
Net tangible assets: 343561000
Owner earnings: 76727000
Return on net tangible assets (%): 22.332860831118783
Capex to operating income (%): 25.425634937990065
Buffett classification: The Good
Stock price: 4.74
P/E ratio: 3.3999097706798773
Shares outstanding: 55019004
Book value: 343561000
P/B ratio: 0.759079403541147
Market cap (USD): 260790078.96
Debt to equity: 0.03383387520702292
Current ratio: 2.259825850955558
Quick ratio: 1.795440461381884
Effective tax rate (%): 28.90641654231507
Interest coverage ratio: 169.37037037037038
COGS to revenue (%): 44.915065323513645
R&D to revenue (%): 9.3854228392449
SG&A to revenue (%): 32.150455712632976
Free cash flow (dilution-adjusted): 141022000
Buyback yield (%): 9.489624796576654
Retained earnings: 3960000
Inventory turnover: 3.1008824904542975
Receivables turnover: 7.703209398876221
Capitalized R&D asset: 128455170
ROCI (R&D-adjusted, %): 20.19011176275914
Rosenberg metric: 0.6232387953442938
FCF margin (%): 19.896441773187732
Revenue growth (%): -0.5274104679329383
Rule of 40 score: 19.369031305254794
Financial ratios for DOCM.SW — annual report dated 2021-12-31
Total revenue: 1897256043.956044
Gross profit: 285764835.16483516
Operating income: -214864835.16483516
Net income: -248060439.56043956
Capital expenditures: 16067032.967032967
Operating cash flow: -143550549.45054945
Depreciation & amortization: 56201098.9010989
Net tangible assets: -121361538.46153846
Owner earnings: -207926373.62637362
Buffett classification: The Gruesome
Stock price: 258.79120879120876
Shares outstanding: 48988533
Book value: 532882417.5824176
P/B ratio: 23.79099263491317
Market cap (USD): 12677801671.97802
Debt to equity: 1.0829595626522148
Current ratio: 2.52727760342905
Quick ratio: 2.092228647247303
Interest coverage ratio: -12.080007413814407
COGS to revenue (%): 84.93799315726645
SG&A to revenue (%): 13.106203696141854
Free cash flow (dilution-adjusted): -213305494.5054945
Buyback yield (%): 3.467166082365905e-05
Retained earnings: -457383516.48351645
Inventory turnover: 15.85976163696141
Receivables turnover: 13.083334596323185
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -18.50395153864426
FCF margin (%): -11.242841744265721
Rule of 40 score: -11.242841744265721
Financial ratios for DOCM.SW — annual report dated 2022-12-31
Total revenue: 1011922826.0869565
Gross profit: 174077173.91304347
Operating income: -163978260.86956522
Net income: -185994565.21739128
Capital expenditures: 13800000
Operating cash flow: -105745652.17391303
Depreciation & amortization: 43088043.47826087
Net tangible assets: -240355434.7826087
Owner earnings: -156706521.7391304
Buffett classification: The Gruesome
Stock price: 27.782608695652172
Shares outstanding: 48988533
Book value: 381281521.7391305
P/B ratio: 3.56961763241243
Market cap (USD): 1361029242.9130435
Debt to equity: 1.5070343435610452
Current ratio: 1.6402968315592772
Quick ratio: 1.2956506967089152
Interest coverage ratio: -8.603364699173083
COGS to revenue (%): 82.79738637913829
SG&A to revenue (%): 14.97343090908505
Free cash flow (dilution-adjusted): -156360869.56521738
Buyback yield (%): 0
Retained earnings: -634686956.5217391
Inventory turnover: 9.266867035345035
Receivables turnover: 7.1972307906394235
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -17.580783502079022
FCF margin (%): -15.451857150989989
Revenue growth (%): -46.663876533134875
Rule of 40 score: -62.11573368412486
Financial ratios for DOCM.SW — annual report dated 2023-12-31
Total revenue: 1154121428.5714285
Gross profit: 242080952.3809524
Operating income: -98294047.61904763
Net income: 97952380.95238096
Capital expenditures: 5769047.619047619
Operating cash flow: -104065476.1904762
Depreciation & amortization: 51709523.80952381
Net tangible assets: -76846428.57142857
Owner earnings: 143892857.14285716
Return on net tangible assets (%): -187.24729283822097
Buffett classification: The Gruesome
Stock price: 87.79761904761905
P/E ratio: 43.90987249331551
Shares outstanding: 48988533
Book value: 512538095.23809534
P/B ratio: 8.391720728656637
Market cap (USD): 4301076558.035714
Debt to equity: 0.7683865543095517
Current ratio: 1.6286359174573948
Quick ratio: 1.3416001641535278
Interest coverage ratio: -4.314296164698505
COGS to revenue (%): 79.02465491169329
SG&A to revenue (%): 12.59461433248544
Free cash flow (dilution-adjusted): -141372619.04761904
Buyback yield (%): 0
Retained earnings: -597354761.9047619
Inventory turnover: 14.801847057459716
Receivables turnover: 17.50342138046834
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -12.03418140690041
FCF margin (%): -12.249371300783322
Revenue growth (%): 14.05231691771845
Rule of 40 score: 1.8029456169351281
Financial ratios for DOCM.SW — annual report dated 2024-12-31
Total revenue: 1130050000
Gross profit: 240603333.3333333
Operating income: -115803333.33333333
Net income: -108058888.88888888
Capital expenditures: 27107777.777777776
Operating cash flow: -29553333.333333332
Depreciation & amortization: 50643333.33333333
Net tangible assets: -171602222.2222222
Owner earnings: -84523333.33333333
Buffett classification: The Gruesome
Stock price: 22.2
Shares outstanding: 48988533
Book value: 377904444.44444436
P/B ratio: 2.877831813274373
Market cap (USD): 1087545432.6
Debt to equity: 0.9179510399454303
Current ratio: 1.8335393808272806
Quick ratio: 1.5152303439276087
Interest coverage ratio: -5.333555089299422
COGS to revenue (%): 78.70861171334602
SG&A to revenue (%): 15.5819064053213
Free cash flow (dilution-adjusted): -61341111.11111111
Buyback yield (%): 0
Retained earnings: -663256666.6666666
Inventory turnover: 21.590840435861473
Receivables turnover: 18.832422923803353
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -15.751840835721282
FCF margin (%): -5.42817672767675
Revenue growth (%): -2.085692889458274
Rule of 40 score: -7.513869617135024
Financial ratios for DOCM.SW — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: -171602222.2222222
Buffett classification: The Gruesome
Stock price: 22.2
Shares outstanding: 48988533
Book value: 377904444.44444436
P/B ratio: 2.877831813274373
Market cap (USD): 1087545432.6
Debt to equity: 0.9179510399454303
Current ratio: 1.8335393808272806
Quick ratio: 1.5152303439276087
Buyback yield (%): 0
Retained earnings: -663256666.6666666
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOYU — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.86
Shares outstanding: 30178859
Market cap (USD): 146669254.74
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOYU — annual report dated 2022-12-31
Total revenue: 1021298613.7931035
Gross profit: 142257191.37931034
Operating income: -30539806.896551725
Net income: -10836552.873563219
Capital expenditures: 795231.4655172414
Operating cash flow: -9746178.879310345
Depreciation & amortization: 12571020.833333334
Net tangible assets: 925291908.4770114
Owner earnings: 939236.4942528737
Buffett classification: The Gruesome
Stock price: 2.58
Shares outstanding: 30178859
Book value: 942609216.5229883
P/B ratio: 0.08260205274377468
Market cap (USD): 77861456.22
Debt to equity: 0.007171756061334987
Current ratio: 4.540544278304655
Quick ratio: 4.540544278304655
COGS to revenue (%): 86.07095031188116
R&D to revenue (%): 5.389396064528591
SG&A to revenue (%): 13.056856608344638
Free cash flow (dilution-adjusted): -22807586.781609192
Buyback yield (%): 20.107785196797458
Retained earnings: -505822531.1781609
Receivables turnover: 15.269613552423172
Capitalized R&D asset: 55041827.29885057
ROCI (R&D-adjusted, %): 0.6146096496308585
FCF margin (%): -2.233194726163566
Rule of 40 score: -2.233194726163566
Financial ratios for DOYU — annual report dated 2023-12-31
Total revenue: 777834677.4964838
Gross profit: 96207214.20534459
Operating income: -20805270.182841066
Net income: 4995447.819971871
Capital expenditures: 710709.8452883263
Operating cash flow: -6707063.150492264
Depreciation & amortization: 13620524.894514767
Net tangible assets: 923859190.9985934
Owner earnings: 17905262.86919831
Return on net tangible assets (%): 1.9380943593627755
Buffett classification: The Gruesome
Stock price: 1.75
P/E ratio: 10.572225985196535
Shares outstanding: 30178859
Book value: 940834456.5400844
P/B ratio: 0.05613421456120947
Market cap (USD): 52813003.25
Debt to equity: 0.0032093684145984595
Current ratio: 4.858350877104069
Quick ratio: 4.858350877104069
Effective tax rate (%): 1.56744813991583
COGS to revenue (%): 87.63140587727533
R&D to revenue (%): 5.007509579918061
SG&A to revenue (%): 10.658939358312843
Free cash flow (dilution-adjusted): -8999992.12376934
Buyback yield (%): 0
Retained earnings: -490155721.9409282
Receivables turnover: 12.640131017053326
Capitalized R&D asset: 75828170.28179106
ROCI (R&D-adjusted, %): -1.2957661556337505
Rosenberg metric: -0.8366360535949613
FCF margin (%): -1.1570571979043738
Revenue growth (%): -23.8386631498886
Rule of 40 score: -24.995720347792975
Financial ratios for DOYU — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.14
Shares outstanding: 30178859
Market cap (USD): 124940476.25999999
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOYU — quarterly report dated 2024-12-31
Total revenue: 155616363.83561644
Gross profit: 9560340
Operating income: 5045020
Net income: -23711272.05479452
Capital expenditures: 0
Net tangible assets: 568379744.3835616
Owner earnings: -23711272.05479452
Return on net tangible assets (%): -4.171730658788812
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 4.28
Shares outstanding: 30178859
Book value: 576724551.5068494
P/B ratio: 0.2239639637024643
Market cap (USD): 129165516.52000001
Debt to equity: 0.003724529376518254
Current ratio: 3.6274341812009503
Quick ratio: 3.6274341812009503
COGS to revenue (%): 93.85646871295685
R&D to revenue (%): 3.0061704536590903
SG&A to revenue (%): 13.294217457794277
Buyback yield (%): 0
Retained earnings: -519427050.5479452
Receivables turnover: 3.3108854685884164
Capitalized R&D asset: 4678093.150684931
ROCI (R&D-adjusted, %): 1.402751527003761
Rule of 40 score: 0
Financial ratios for DOYU — annual report dated 2024-12-31
Total revenue: 585044583.0136987
Gross profit: 44360613.97260274
Operating income: -47103747.12328767
Net income: -42028806.30136986
Capital expenditures: 36465.75342465754
Operating cash flow: -32719443.287671234
Depreciation & amortization: 8576481.643835617
Net tangible assets: 568379744.3835616
Owner earnings: -33488790.4109589
Return on net tangible assets (%): -5.891974642284146
Buffett classification: The Gruesome
Stock price: 4.28
Shares outstanding: 30178859
Book value: 576724551.5068494
P/B ratio: 0.2239639637024643
Market cap (USD): 129165516.52000001
Debt to equity: 0.003724529376518254
Current ratio: 3.6274341812009503
Quick ratio: 3.6274341812009503
COGS to revenue (%): 92.41756692385884
R&D to revenue (%): 4.25388679241777
SG&A to revenue (%): 12.07188735085595
Free cash flow (dilution-adjusted): -34516935.20547945
Buyback yield (%): 11.189745629583788
Retained earnings: -519427050.5479452
Receivables turnover: 12.447377387782744
Capitalized R&D asset: 69147535.06954204
ROCI (R&D-adjusted, %): -9.566545009327347
Rosenberg metric: -1.3311015636237864
FCF margin (%): -5.899881172760341
Revenue growth (%): -24.785484635796095
Rule of 40 score: -30.685365808556437
Financial ratios for DOYU — quarterly report dated 2025-03-31
Total revenue: 130447796.14325069
Gross profit: 15634710.743801653
Operating income: -3600826.4462809917
Net income: -10965840.220385674
Capital expenditures: 0
Net tangible assets: 264340495.86776862
Owner earnings: -10965840.220385674
Return on net tangible assets (%): -4.148376957676258
Buffett classification: The Gruesome
Stock price: 7.47
Shares outstanding: 30178859
Book value: 271577272.72727275
P/B ratio: 0.8300991996351279
Market cap (USD): 225436076.73
Debt to equity: 0.006342400353815152
Current ratio: 1.87532581107721
Quick ratio: 1.87532581107721
COGS to revenue (%): 88.01458421985721
R&D to revenue (%): 3.4579975101657676
SG&A to revenue (%): 11.47942402257112
Buyback yield (%): 0
Retained earnings: -533254683.1955923
Receivables turnover: 8.548471828570397
Capitalized R&D asset: 7645203.953658629
ROCI (R&D-adjusted, %): -0.7701572047797738
Rosenberg metric: 1.2984715242175735
Revenue growth (%): -16.17347113890431
Rule of 40 score: -16.17347113890431
Financial ratios for DOYU — quarterly report dated 2025-06-30
Total revenue: 146989539.74895397
Gross profit: 19796373.779637378
Operating income: 1986889.818688982
Net income: 5276011.157601116
Capital expenditures: 0
Net tangible assets: 273338493.72384936
Owner earnings: 5276011.157601116
Return on net tangible assets (%): 1.9302115431028195
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 6.48
P/E ratio: 9.266423083576093
Shares outstanding: 30178859
Book value: 279641701.53417015
P/B ratio: 0.6993198984526424
Market cap (USD): 195559006.32000002
Debt to equity: 0.006160503254064401
Current ratio: 2.0751979986819453
Quick ratio: 2.0751979986819453
Effective tax rate (%): 19.003543784388697
COGS to revenue (%): 86.53212071182212
R&D to revenue (%): 2.619850746976749
SG&A to revenue (%): 9.62136415175797
Buyback yield (%): 0
Retained earnings: -534672245.46722454
Receivables turnover: 8.733933321731348
Capitalized R&D asset: 8416967.928425498
ROCI (R&D-adjusted, %): 0.5176065259342875
Rosenberg metric: 0.9225830907865082
Revenue growth (%): 12.680738268309288
Rule of 40 score: 12.680738268309288
Financial ratios for DOYU — quarterly report dated 2025-09-30
Total revenue: 126279634.83146067
Gross profit: 16304634.831460673
Operating income: 1675561.797752809
Net income: 1591151.6853932585
Capital expenditures: 0
Net tangible assets: 275821769.66292137
Owner earnings: 1591151.6853932585
Return on net tangible assets (%): 0.5768767589801873
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 7.52
P/E ratio: 35.657351490016765
Shares outstanding: 30178859
Book value: 281456741.5730337
P/B ratio: 0.8063229127560665
Market cap (USD): 226945019.67999998
Debt to equity: 0.004865337439844469
Current ratio: 2.2622611179918786
Quick ratio: 2.2622611179918786
Effective tax rate (%): 33.853346206616195
COGS to revenue (%): 87.0884684983278
R&D to revenue (%): 2.990509514398111
SG&A to revenue (%): 9.743513314818749
Buyback yield (%): 0
Retained earnings: -536835814.60674155
Receivables turnover: 6.176527969553957
Capitalized R&D asset: 7845102.79538367
ROCI (R&D-adjusted, %): 0.4855031918579008
Rosenberg metric: -0.9067316742757223
Revenue growth (%): -14.089373266195752
Rule of 40 score: -14.089373266195752
Financial ratios for DOYU — annual report dated 2025-12-31
Total revenue: 545550239.8571428
Gross profit: 69932334.71428572
Operating income: 1551410.2857142857
Net income: -4154560.714285714
Capital expenditures: 8038.285714285715
Operating cash flow: -7464973.714285715
Depreciation & amortization: 4509549.428571428
Net tangible assets: 279113146.4285714
Owner earnings: 346950.42857142835
Capex to operating income (%): 0.5181276538066011
Buffett classification: The Great
Stock price: 6.8
Shares outstanding: 30178859
Book value: 283910275.71428573
P/B ratio: 0.7228207597759518
Market cap (USD): 205216241.2
Debt to equity: 0.004030084092009893
Current ratio: 2.326497350735538
Quick ratio: 2.326497350735538
Effective tax rate (%): 2264.526059701683
COGS to revenue (%): 87.18132087475608
R&D to revenue (%): 3.170017800526366
SG&A to revenue (%): 9.744778883306823
Free cash flow (dilution-adjusted): -7720656.714285715
Buyback yield (%): 0
Retained earnings: -545842770.5714285
Receivables turnover: 11.053355595079163
Capitalized R&D asset: 46821967.836706385
ROCI (R&D-adjusted, %): -2.47744203390114
Rosenberg metric: 1.027507646654891
FCF margin (%): -1.4152054476792895
Revenue growth (%): -6.750655301021929
Rule of 40 score: -8.165860748701219
Financial ratios for DOYU — quarterly report dated 2025-12-31
Total revenue: 131253525.57142857
Gross profit: 16855763.285714287
Operating income: 1546553.142857143
Net income: 196010.7142857143
Capital expenditures: 0
Net tangible assets: 279113146.4285714
Owner earnings: 196010.7142857143
Return on net tangible assets (%): 0.07022625655358586
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 6.8
P/E ratio: 261.7411016890476
Shares outstanding: 30178859
Book value: 283910275.71428573
P/B ratio: 0.7228207597759518
Market cap (USD): 205216241.2
Debt to equity: 0.004030084092009893
Current ratio: 2.326497350735538
Quick ratio: 2.326497350735538
Effective tax rate (%): 65.1944639437729
COGS to revenue (%): 87.15785864621112
R&D to revenue (%): 3.679931410038348
SG&A to revenue (%): 8.09955408011413
Buyback yield (%): 0
Retained earnings: -545842770.5714285
Receivables turnover: 2.6593185838003093
Capitalized R&D asset: 8631029.888701586
ROCI (R&D-adjusted, %): 0.7597985425834723
Rosenberg metric: 0.1459399953245214
Revenue growth (%): 3.9387908799437925
Rule of 40 score: 3.9387908799437925
Financial ratios for DRX.TO — annual report dated 2022-01-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.328125
Shares outstanding: 16476336
Market cap (USD): 21882633.75
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DRX.TO — annual report dated 2023-01-31
Total revenue: 187231343.2835821
Gross profit: 26544029.850746267
Operating income: 15519402.985074626
Net income: 11145522.3880597
Capital expenditures: 8554477.611940298
Operating cash flow: -1949253.7313432836
Depreciation & amortization: 3972388.059701492
Net tangible assets: 90555970.14925373
Owner earnings: 6563432.835820895
Return on net tangible assets (%): 7.247929457332399
Capex to operating income (%): 55.12117714945182
Buffett classification: The Good
Stock price: 1.5522388059701493
P/E ratio: 2.2946621278875132
Shares outstanding: 16476336
Book value: 93272388.05970149
P/B ratio: 0.27419913493619236
Market cap (USD): 25575208.119402986
Debt to equity: 0.4122014641757011
Current ratio: 1.7388855723634562
Quick ratio: 1.618600826753472
Effective tax rate (%): 11.386021122582177
Interest coverage ratio: 10.51896813353566
COGS to revenue (%): 85.8228705807326
SG&A to revenue (%): 5.888237873171509
Free cash flow (dilution-adjusted): -11564925.373134326
Buyback yield (%): 0
Retained earnings: 31579104.477611937
Inventory turnover: 20.163030246277742
Receivables turnover: 1.8698575005962321
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.374127633507625
FCF margin (%): -6.1768105544262415
Rule of 40 score: -6.1768105544262415
Financial ratios for DRX.TO — annual report dated 2024-01-31
Total revenue: 247032089.5522388
Gross profit: 54418656.71641791
Operating income: 37417164.17910448
Net income: 28076119.402985074
Capital expenditures: 4304477.611940298
Operating cash flow: 58104477.611940295
Depreciation & amortization: 4328358.208955224
Net tangible assets: 118063432.83582088
Owner earnings: 28100000
Return on net tangible assets (%): 23.80076483044152
Capex to operating income (%): 11.504018827659108
Buffett classification: The Great
Stock price: 5.910447761194029
P/E ratio: 3.4685179182393275
Shares outstanding: 16476336
Book value: 120992537.31343283
P/B ratio: 0.8048638815765127
Market cap (USD): 97382523.22388059
Debt to equity: 0.3012644174427928
Current ratio: 2.0438393568205093
Quick ratio: 1.915525806818613
Effective tax rate (%): 18.928586820669743
Interest coverage ratio: 13.877387212842516
COGS to revenue (%): 77.97101711965634
SG&A to revenue (%): 6.882301229823909
Free cash flow (dilution-adjusted): 49847761.194029845
Buyback yield (%): 0
Retained earnings: 59167910.44776119
Inventory turnover: 19.07063691443771
Receivables turnover: 2.628564395353085
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 22.470857665296755
FCF margin (%): 20.17865828054244
Revenue growth (%): 31.939495396388846
Rule of 40 score: 52.118153676931286
Financial ratios for DRX.TO — quarterly report dated 2024-10-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 7.266187050359712
Shares outstanding: 16476336
Market cap (USD): 119720139.28057554
Buyback yield (%): 0.06009218371736229
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DRX.TO — annual report dated 2025-01-31
Total revenue: 234228965.5172414
Gross profit: 73959310.34482759
Operating income: 58709655.172413796
Net income: 39165517.24137931
Capital expenditures: 5712413.793103448
Operating cash flow: 37969655.172413796
Depreciation & amortization: 4248275.862068966
Net tangible assets: 113782068.96551724
Owner earnings: 37701379.31034483
Return on net tangible assets (%): 33.13472821606944
Capex to operating income (%): 9.729939268639358
Buffett classification: The Great
Stock price: 5.482758620689656
P/E ratio: 2.306512963549921
Shares outstanding: 16476336
Book value: 116766896.55172414
P/B ratio: 0.7736419816669817
Market cap (USD): 90335773.24137932
Debt to equity: 0.26949655074655077
Current ratio: 2.358641284061217
Quick ratio: 2.1908050267512755
Effective tax rate (%): 27.57024245284222
Interest coverage ratio: 25.664455833584565
COGS to revenue (%): 68.42435341781693
SG&A to revenue (%): 6.510576153012673
Free cash flow (dilution-adjusted): 30742758.620689657
Buyback yield (%): 41.66371751614142
Retained earnings: 59202068.965517245
Inventory turnover: 17.228185929275707
Receivables turnover: 3.032780590604266
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 37.414900209645445
FCF margin (%): 13.125088330899326
Revenue growth (%): -5.182777694267927
Rule of 40 score: 7.942310636631398
Financial ratios for DRX.TO — quarterly report dated 2025-01-31
Total revenue: 53378620.68965518
Gross profit: 16549655.172413794
Operating income: 12162758.620689655
Net income: 6271034.482758621
Capital expenditures: 822758.6206896552
Operating cash flow: 1212413.7931034483
Depreciation & amortization: 1108965.5172413792
Net tangible assets: 113782068.96551724
Owner earnings: 6557241.379310345
Return on net tangible assets (%): 5.762983077146876
Capex to operating income (%): 6.764572465411659
Buffett classification: The Great
Stock price: 5.482758620689656
P/E ratio: 3.601310656548994
Shares outstanding: 16476336
Book value: 116766896.55172414
P/B ratio: 0.7736419816669817
Market cap (USD): 90335773.24137932
Debt to equity: 0.26949655074655077
Current ratio: 2.358641284061217
Quick ratio: 2.358641284061217
Effective tax rate (%): 30.756929637526646
Interest coverage ratio: 7.32696302451184
COGS to revenue (%): 68.99572345895942
SG&A to revenue (%): 8.218452434785977
Free cash flow (dilution-adjusted): 926206.8965517242
Buyback yield (%): 0
Retained earnings: 59202068.965517245
Receivables turnover: 0.6911427219230803
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.751167993249151
FCF margin (%): 1.7351645370095221
Rule of 40 score: 1.7351645370095221
Financial ratios for DRX.TO — quarterly report dated 2025-04-30
Total revenue: 40234057.97101449
Gross profit: 8832608.695652174
Operating income: 6381159.420289855
Net income: 6337681.15942029
Capital expenditures: 760144.9275362319
Operating cash flow: 18336956.521739133
Depreciation & amortization: 1151449.2753623188
Net tangible assets: 117945652.17391305
Owner earnings: 6728985.507246377
Return on net tangible assets (%): 5.705157742757963
Capex to operating income (%): 11.912332500567794
Buffett classification: The Great
Stock price: 4.384057971014493
P/E ratio: 2.8493549279670707
Shares outstanding: 16476336
Book value: 121342753.62318842
P/B ratio: 0.5952824541811732
Market cap (USD): 72233212.17391305
Debt to equity: 0.2659134204821651
Current ratio: 2.4497985000934106
Quick ratio: 2.262203421495103
Effective tax rate (%): 25.451755881350152
Interest coverage ratio: 518
COGS to revenue (%): 78.04693550420548
SG&A to revenue (%): 6.092970480701691
Free cash flow (dilution-adjusted): 18558695.652173914
Buyback yield (%): 5.099224058408365
Retained earnings: 65825362.318840586
Inventory turnover: 3.0825152937828992
Receivables turnover: 0.6070143983207424
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.920905111959072
FCF margin (%): 46.12683032256903
Revenue growth (%): -24.625144952814626
Rule of 40 score: 21.5016853697544
Financial ratios for DRX.TO — quarterly report dated 2025-07-31
Total revenue: 38410144.927536234
Gross profit: 7935507.246376812
Operating income: 1550000.0000000002
Net income: 650724.6376811594
Capital expenditures: 392028.9855072464
Operating cash flow: -13210144.927536232
Depreciation & amortization: 1132608.695652174
Net tangible assets: 116350724.63768117
Owner earnings: 1391304.3478260871
Return on net tangible assets (%): 1.1957848583742308
Capex to operating income (%): 25.292192613370734
Buffett classification: The Good
Stock price: 6.405797101449275
P/E ratio: 7.959918606188569
Shares outstanding: 16476336
Book value: 120313768.11594205
P/B ratio: 0.8772401284082079
Market cap (USD): 105544065.39130434
Debt to equity: 0.2619780405100191
Current ratio: 2.2365247354171798
Quick ratio: 2.02170575343108
Effective tax rate (%): 27.463651050080774
Interest coverage ratio: 28.905405405405407
COGS to revenue (%): 79.34007470852357
SG&A to revenue (%): 16.62453307172773
Free cash flow (dilution-adjusted): -16505797.101449277
Buyback yield (%): 1.7541955281882273
Retained earnings: 65397826.08695652
Inventory turnover: 2.2944514157891867
Receivables turnover: 0.4571886940546322
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.9658978017809728
FCF margin (%): -42.97249367996076
Revenue growth (%): -4.533256488302138
Rule of 40 score: -47.5057501682629
Financial ratios for DRX.TO — quarterly report dated 2025-10-31
Total revenue: 51009285.71428572
Gross profit: 14076428.571428573
Operating income: 11868571.42857143
Net income: 7363571.428571429
Capital expenditures: 3160000
Operating cash flow: 4312142.857142857
Depreciation & amortization: 1241428.5714285716
Net tangible assets: 124296428.57142858
Owner earnings: 5445000
Return on net tangible assets (%): 4.3806568399275925
Capex to operating income (%): 26.624939817043813
Buffett classification: The Good
Stock price: 5.128571428571429
P/E ratio: 4.097367894263276
Shares outstanding: 16476336
Book value: 129422142.85714287
P/B ratio: 0.6529026964915476
Market cap (USD): 84500066.05714287
Debt to equity: 0.23588368075677046
Current ratio: 2.270063758095023
Quick ratio: 2.029336239399747
Effective tax rate (%): 27.401408450704224
Interest coverage ratio: 50.04819277108434
COGS to revenue (%): 72.40418411213643
SG&A to revenue (%): 4.3283435789002
Free cash flow (dilution-adjusted): 1460000.0000000002
Buyback yield (%): 0
Retained earnings: 71407857.14285715
Inventory turnover: 2.6904984909980225
Receivables turnover: 0.583511051190914
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.986767358643686
FCF margin (%): 2.862223964824332
Revenue growth (%): 32.801596584753206
Rule of 40 score: 35.66382054957754
Financial ratios for DRX.TO — quarterly report dated 2026-01-31
Total revenue: 58365925.925925925
Gross profit: 12537037.037037035
Operating income: 6681481.481481481
Net income: 9154074.074074073
Capital expenditures: 1028148.1481481481
Operating cash flow: 26680740.74074074
Depreciation & amortization: 1503703.7037037036
Net tangible assets: 129750370.37037036
Owner earnings: 9629629.629629629
Return on net tangible assets (%): 7.421658683626109
Capex to operating income (%): 15.388026607538801
Buffett classification: The Great
Stock price: 6.533333333333333
P/E ratio: 4.5794758901576476
Shares outstanding: 16476336
Book value: 136003703.7037037
P/B ratio: 0.7914887041202581
Market cap (USD): 107645395.2
Debt to equity: 0.22672585169249201
Current ratio: 2.207820945751265
Quick ratio: 1.982297417220833
Effective tax rate (%): 15.489297681734254
Interest coverage ratio: 4.118721461187215
COGS to revenue (%): 78.51993806635022
SG&A to revenue (%): 10.032489783486051
Free cash flow (dilution-adjusted): 23851111.111111112
Buyback yield (%): 0.7411164929958637
Retained earnings: 78815555.55555555
Inventory turnover: 3.161743663123467
Receivables turnover: 0.7825016137841999
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.7286902458785987
FCF margin (%): 40.86478665888266
Revenue growth (%): 14.422158845443114
Rule of 40 score: 55.28694550432577